Porous silicate/magnetic ferrite nanocarrier for combination anti-cancer therapeutic and antioxidant delivery

Patent metadata

Field	Value
Publication number	US-2022401572-A1
Application number	US-202117351758-A
Country	US
Kind code	A1
Filing date	Jun 18, 2021
Priority date	Jun 18, 2021
Publication date	Dec 22, 2022
Grant date	—

Abstract

A nanomedicinal composition comprising a nanocarrier and a pharmaceutical agent mixture comprising an anti-cancer therapeutic and an antioxidant. The nanocarrier comprises a porous silicate matrix and particles of a magnetic ferrite disposed in the pores of the porous silicate matrix. The pharmaceutical agent mixture is disposed in the pores and/or on the surface of the nanocarrier by a solution phase impregnation process. The nanomedicinal composition is used in a method of treating breast cancer.

First claim

1 . A nanomedicinal composition comprising:
a nanocarrier comprising:
a porous silicate matrix; and
particles of a magnetic ferrite of formula MFe 2 O 4 disposed in the pores of the porous silicate matrix, where M is at least one transition metal selected from the group consisting of Cu, Ni, Co, and Mn; and
a pharmaceutical agent mixture comprising an anti-cancer therapeutic and an antioxidant, the pharmaceutical agent mixture being disposed in the pores and/or on a surface of the nanocarrier.

2 . The nanomedicinal composition of claim 1 , wherein the porous silicate matrix is at least one selected from the group consisting of MCM-41 and mesosilicalite.

3 . The nanomedicinal composition of claim 1 , wherein the porous silicate matrix is present in the form of particles having a mean particle size of 25 to 500 nm.

4 . The nanomedicinal composition of claim 1 , wherein the magnetic ferrite is copper ferrite of formula CuFe 2 O 4 .

5 . The nanomedicinal composition of claim 1 , wherein the magnetic ferrite is present in an amount of 15 to 45 wt % based on a total weight of the nanocarrier.

6 . The nanomedicinal composition of claim 1 , wherein the magnetic ferrite has a mean particle size of 5 to 50 nm.

7 . The nanomedicinal composition of claim 1 , wherein the anti-cancer therapeutic comprises a platinum (II) complex.

8 . The nanomedicinal composition of claim 7 , wherein the platinum (II) complex is at least one selected from the group consisting of cisplatin, carboplatin, and oxaliplatin.

9 . The nanomedicinal composition of claim 8 , wherein the platinum (II) complex is cisplatin.

10 . The nanomedicinal composition of claim 1 , wherein the anti-cancer therapeutic comprises tamoxifen.

11 . The nanomedicinal composition of claim 1 , wherein the antioxidant is at least one selected from the group consisting of quercetin, rutin, coenzyme Q10, gallic acid and curcumin.

12 . The nanomedicinal composition of claim 11 , wherein the antioxidant is curcumin.

13 . The nanomedicinal composition of claim 1 , wherein a weight ratio of the antioxidant to the anti-cancer therapeutic is 1:1 to 10:1.

14 . The nanomedicinal composition of claim 1 , wherein the pharmaceutical agent mixture is present in the nanomedicinal composition in an amount of 5 to 50 wt %, based on a total weight of nanomedicinal composition.

15 . A method of forming the nanomedicinal composition of claim 1 , the method comprising:
mixing an M(II) salt and a Fe(III) salt with the porous silicate matrix to form a powdery mixture; calcining the powdery mixture to form the nanocarrier; mixing the nanocarrier and the anti-cancer therapeutic in an aqueous solution thereby forming a therapeutic-containing nanocarrier; and mixing the therapeutic-containing nanocarrier and the antioxidant in an impregnation solution thereby forming the nanomedicinal composition.

16 . The method of claim 15 , wherein the calcining is performed at a temperature of 700 to 1,000° C.

17 . The method of claim 15 , wherein:
the aqueous solution is a saline; the anti-cancer therapeutic is present in the aqueous solution at a concentration of 1.0 to 20.0 mM; and the nanocarrier is present in the aqueous solution at a concentration of 20 to 100 mg/mL.

18 . The method of claim 15 , wherein:
the impregnation solution comprises an alcohol solvent; the antioxidant is present in the impregnation solution at a concentration of 1.0 to 20.0 mM; and the therapeutic-containing nanocarrier is present in the impregnation solution at a concentration of 2 to 30 mg/mL.

19 . A method for treating a cancer in a subject, comprising administering to a subject in need of therapy a pharmaceutical composition comprising the nanomedicinal composition of claim 1 , wherein the cancer is at least one selected from the group consisting of breast cancer, colorectal cancer, and lung cancer.

20 . The method of claim 19 , further comprising exposing the subject to an alternating magnetic field after the administering, thereby raising the temperature of the nanomedicinal composition.

Assignees

• Univ Imam Abdulrahman Bin Faisal

Inventors

• Jermy B Rabindran
• Ravinayagam Vijaya
• Almohazey Dana

Classifications

• A61K9/5115

  Inorganic compounds · CPC title

• A61K33/243

  Platinum; Compounds thereof · CPC title

• A61K31/138

  Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377) · CPC title

• A61K31/282 Primary

  Platinum compounds · CPC title

• B82Y5/00

  Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery · CPC title